

Supplemental Figures for:
Anlotinib, Vincristine and Irinotecan (AVI) for Advanced Ewing Sarcoma after Failure of Standard Multimodal
Therapy: A Two-cohort, Phase Ib/II Trial
Wei Guo et al.




Figure S1a.

Supplemental Figures for:
Anlotinib, Vincristine and Irinotecan (AVI) for Advanced Ewing Sarcoma after Failure of Standard Multimodal Therapy: A Two-cohort, Phase Ib/II Trial
Wei Guo et al.




Figure S1B.

Supplemental Figures for:
Anlotinib, Vincristine and Irinotecan (AVI) for Advanced Ewing Sarcoma after Failure of Standard Multimodal
Therapy: A Two-cohort, Phase Ib/II Trial
Wei Guo et al.

Figure

Figure S2a.

Supplemental Figures for:
Anlotinib, Vincristine and Irinotecan (AVI) for Advanced Ewing Sarcoma after Failure of Standard Multimodal
Therapy: A Two-cohort, Phase Ib/II Trial
Wei Guo et al.




Figure S2b

Supplemental Figures for:
Anlotinib, Vincristine and Irinotecan (AVI) for Advanced Ewing Sarcoma after Failure of Standard Multimodal Therapy: A Two-cohort, Phase Ib/II Trial
Wei Guo et al.




Figure S3.

Supplemental Figures for:
 Anlotinib, Vincristine and Irinotecan (AVI) for Advanced Ewing Sarcoma after Failure of Standard Multimodal
 Therapy: A Two-cohort, Phase Ib/II Trial
 Wei Guo et al.




Figure S4.